EMISPHERE COMPLETES ENROLLMENT FOR ORAL INSULIN TRIAL
Emisphere Technologies has completed enrollment of the first 120 patients in its Phase II oral insulin clinical trial and has received permission from regulatory authorities in India to expand the trial enrollment from 120 patients to 140 patients. Based on the current enrollment rate, the company expects to complete the additional enrollment within the next few weeks.
There have been no reported cases of treatment-related serious adverse events or hypoglycemia, which is commonly observed in diabetic patients treated with insulin. One of the primary objectives of the trial is to test the hypothesis that oral insulin can be administered as a fixed dose without the need to frequently monitor patients' blood.